Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE)
CUSIP: 90400D108
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / COMMON STOCK
- Shares outstanding
- 98,459,627
- Total 13F shares
- 93,871,464
- Share change
- -1,662,673
- Total reported value
- $2,156,995,771
- Put/Call ratio
- 64%
- Price per share
- $23.00
- Number of holders
- 284
- Value change
- -$89,024,892
- Number of buys
- 154
- Number of sells
- 155
Quarterly Holders Quick Answers
What is CUSIP 90400D108?
CUSIP 90400D108 identifies RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 90400D108:
Top shareholders of RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
|
Company |
10%
|
10,132,728
|
$304,792,459 | — | 30 Sep 2025 | |
| FMR LLC |
13F
13D/G
|
Company |
3.5%
from 13D/G
|
7,283,296
|
$219,081,558 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
5.1%
from 13D/G
|
6,425,263
|
$193,271,911 | — | 30 Sep 2025 | |
| SANDS CAPITAL MANAGEMENT, LLC |
13D/G
13F
|
Company |
4.7%
|
4,298,003
|
$163,238,154 | $0 | 31 Dec 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
4.1%
|
4,011,429
|
$120,663,796 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
3.8%
|
3,692,487
|
$111,070,009 | — | 30 Sep 2025 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
3.3%
|
3,258,266
|
$98,008,641 | — | 30 Sep 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13D/G
13F
|
Company |
2.7%
|
2,457,543
|
$93,337,483 | $0 | 31 Dec 2024 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
2.8%
|
2,772,692
|
$83,402,575 | — | 30 Sep 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
2.3%
|
2,310,174
|
$69,491,000 | — | 30 Sep 2025 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
2.2%
|
2,167,729
|
$65,205,288 | — | 30 Sep 2025 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.1%
|
2,019,000
|
$60,731,520 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.6%
|
1,580,507
|
$47,551,518 | — | 30 Sep 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
1.6%
|
1,546,101
|
$46,506,718 | — | 30 Sep 2025 | |
| BNP Paribas Asset Management Holding S.A. |
13F
|
Company |
1.6%
|
1,545,279
|
$46,482,000 | — | 30 Sep 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
1.5%
|
1,458,187
|
$43,988,784 | — | 30 Sep 2025 | |
| Rock Springs Capital Management LP |
13F
|
Company |
1.3%
|
1,246,341
|
$37,489,937 | — | 30 Sep 2025 | |
| GW&K Investment Management, LLC |
13F
|
Company |
1.2%
|
1,150,169
|
$34,597,000 | — | 30 Sep 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
1.2%
|
1,144,589
|
$34,429,232 | — | 30 Sep 2025 | |
| FRONTIER CAPITAL MANAGEMENT CO LLC |
13F
|
Company |
1.1%
|
1,069,098
|
$32,158,463 | — | 30 Sep 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
1%
|
983,715
|
$29,590,147 | — | 30 Sep 2025 | |
| Aberdeen Group plc |
13F
|
Company |
0.99%
|
973,656
|
$29,287,572 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.92%
|
910,183
|
$27,378,343 | — | 30 Sep 2025 | |
| Russell Investments Group, Ltd. |
13F
|
Company |
0.85%
|
840,451
|
$25,280,799 | — | 30 Sep 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.81%
|
794,849
|
$23,909,058 | — | 30 Sep 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.77%
|
754,714
|
$22,701,797 | — | 30 Sep 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
0.76%
|
750,000
|
$22,560,000 | — | 30 Sep 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.76%
|
746,182
|
$22,445,155 | — | 30 Sep 2025 | |
| Eagle Health Investments LP |
13F
|
Company |
0.71%
|
697,000
|
$20,965,760 | — | 30 Sep 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.69%
|
682,144
|
$20,518,892 | — | 30 Sep 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.69%
|
677,184
|
$20,369,695 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.67%
|
655,021
|
$19,703,032 | — | 30 Sep 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.61%
|
603,397
|
$18,150,182 | — | 30 Sep 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.61%
|
600,160
|
$18,052,813 | — | 30 Sep 2025 | |
| BRAIDWELL LP |
13F
|
Company |
0.6%
|
588,700
|
$17,708,096 | — | 30 Sep 2025 | |
| Polar Capital Holdings Plc |
13F
|
Company |
0.59%
|
583,710
|
$17,557,997 | — | 30 Sep 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.58%
|
573,019
|
$17,236,412 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.56%
|
547,025
|
$16,454,512 | — | 30 Sep 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.54%
|
531,996
|
$16,002,440 | — | 30 Sep 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.53%
|
517,700
|
$15,572,416 | — | 30 Sep 2025 | |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ |
13F
|
Company |
0.51%
|
501,163
|
$15,074,983 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.51%
|
499,232
|
$15,016,899 | — | 30 Sep 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.5%
|
496,060
|
$14,921,485 | — | 30 Sep 2025 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.49%
|
482,582
|
$14,516,067 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.48%
|
476,938
|
$14,346,295 | — | 30 Sep 2025 | |
| FRED ALGER MANAGEMENT, LLC |
13F
|
Company |
0.46%
|
448,717
|
$13,497,408 | — | 30 Sep 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.44%
|
430,000
|
$12,934,400 | — | 30 Sep 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.43%
|
425,351
|
$12,794,558 | — | 30 Sep 2025 | |
| Blue Owl Capital Holdings LP |
13F
|
Company |
0.43%
|
422,438
|
$12,706,935 | — | 30 Sep 2025 | |
| EMERALD ADVISERS, LLC |
13F
|
Company |
0.43%
|
418,566
|
$12,590,465 | — | 30 Sep 2025 |
Institutional Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q4 2025
As of 31 Dec 2025,
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) was held by
284 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
93,871,464 shares.
The largest 10 holders included
VANGUARD GROUP INC, BlackRock, Inc., STATE STREET CORP, JPMORGAN CHASE & CO, SANDS CAPITAL MANAGEMENT, LLC, RTW INVESTMENTS, LP, BAKER BROS. ADVISORS LP, FMR LLC, WELLINGTON MANAGEMENT GROUP LLP, and CITADEL ADVISORS LLC.
This page lists
284
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
301
Q4 2025 holders
284
Holder diff
-17
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.